{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-025064","form_type":"8-K","ticker":"GNPX","cik":"0001595248","company_name":"Genprex, Inc.","filed_at":"2023-09-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.479875+00:00","generated_at":"2026-06-11T00:31:34.432681+00:00","sec_items":["3.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Genprex receives Nasdaq deficiency notice for bid price below $1.00; 180 days to cure","bullets":["Received Nasdaq letter on Aug 30, 2023 for failing Minimum Bid Price Requirement (bid <$1.00 for 30 consecutive trading days).","Granted 180 calendar days until Feb 26, 2024 to regain compliance by having bid >=$1.00 for 10 consecutive business days.","If not cured by Feb 26, may be eligible for extra 180-day period if meeting other listing standards and intends reverse split.","No immediate effect on listing; trading continues on Nasdaq Capital Market.","Company monitoring and assessing actions; no assurance of regaining compliance."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-025064","json":"https://secwatch.observer/filing/0001437749-23-025064.json","markdown":"https://secwatch.observer/filing/0001437749-23-025064.md","text":"https://secwatch.observer/filing/0001437749-23-025064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595248/000143774923025064/0001437749-23-025064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595248/000143774923025064/gnpx20230829c_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T00:31:34.432681+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4637ff79415c38352408c7a627da8ba74b9160cb","claim":"Genprex, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"August 30, 2023, Genprex, Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, based upon the closing bid price of the Company’s common stock, par value $0.001 per share (“Common Stock”), for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Nasd","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1595248/000143774923025064/0001437749-23-025064-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}